Role of CD19 CAR T Cells in Second Line Large B Cell Lymphoma: Lessons from Phase 3 Trials – An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.

Since 2017, three CD19 directed chimeric antigen receptor (CAR T-cell) therapies have been approved for relapsed/refractory aggressive large B cell lymphomas (LBCL) after two lines of therapy, axicabtagene ciloleucel (axi-cel, Kite/Gilead), tisagenlecleucel (tisa-cel, Novartis) and lisocabtagene maraleucel (liso-cel, Bristol Myers Squibb) 1-3. The three products have never been compared in a randomized fashion but differences in construct design, manufacturing nuances, and toxicity have influenced clinical implementation 4-7.